Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 3
2012 4
2013 3
2014 1
2016 1
2017 1
2018 4
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y. Janes MR, et al. Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006. Cell. 2018. PMID: 29373830 Free article.
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors.
Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP. Hansen R, et al. Among authors: janes mr. Nat Struct Mol Biol. 2018 Jun;25(6):454-462. doi: 10.1038/s41594-018-0061-5. Epub 2018 May 14. Nat Struct Mol Biol. 2018. PMID: 29760531
The translational landscape of mTOR signalling steers cancer initiation and metastasis.
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. Hsieh AC, et al. Among authors: janes mr. Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912. Nature. 2012. PMID: 22367541 Free PMC article.
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.
Gilardi M, Wang Z, Proietto M, Chillà A, Calleja-Valera JL, Goto Y, Vanoni M, Janes MR, Mikulski Z, Gualberto A, Molinolo AA, Ferrara N, Gutkind JS, Burrows F. Gilardi M, et al. Among authors: janes mr. Mol Cancer Ther. 2020 Sep;19(9):1784-1796. doi: 10.1158/1535-7163.MCT-19-0958. Epub 2020 Jul 29. Mol Cancer Ther. 2020. PMID: 32727882 Free PMC article.
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, Myers DT, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan J, Stein GT, Murchie E, Zarrinkar PP, Janes MR, Li LS, Liu Y, Hata AN, Benes CH. Misale S, et al. Among authors: janes mr. Clin Cancer Res. 2019 Jan 15;25(2):796-807. doi: 10.1158/1078-0432.CCR-18-0368. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327306 Free article.
Next-generation flow cytometry.
Janes MR, Rommel C. Janes MR, et al. Nat Biotechnol. 2011 Jul 11;29(7):602-4. doi: 10.1038/nbt.1919. Nat Biotechnol. 2011. PMID: 21747386 No abstract available.
Targeting TOR dependence in cancer.
Janes MR, Fruman DA. Janes MR, et al. Oncotarget. 2010 May;1(1):69-76. doi: 10.18632/oncotarget.110. Oncotarget. 2010. PMID: 20657741 Free PMC article.
21 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page